P harmacological agents that are based on the gut-derived hormone glucagon-like peptide (GLP)-1 are increasingly used for hyperglycemia management in type 2 diabetes mellitus. Both GLP-1 receptor agonists and inhibitors of the GLP-1-degrading enzyme dipeptidyl peptidase-4 (ie, DPP-4 inhibitors) increase insulin and reduce glucagon secretion, thereby lowering plasma glucose levels. 1 Moreover, GLP-1 receptor agonists reduce appetite, gastric emptying rate, and bodyweight, whereas both antihyperglycemic drug classes improve blood pressure and (postprandial) lipid profiles in patients with type 2 diabetes mellitus. 2 The microcirculation encompasses all vessels of <150 µm, which includes arterioles, capillaries, and venules, and is involved in regulation of tissue perfusion to optimize nutrient delivery. An increase in microvascular perfusion improves glucose and insulin supply to the muscle interstitium, thereby enhancing peripheral glucose disposal. In addition, the microcirculation regulates peripheral vascular resistance, which in conjunction with cardiac output determines arterial blood pressure. 3 GLP-1 peptide has been shown to improve microvascular function. 4 As such, GLP-1 infusion increased microvascular perfusion of skeletal muscle in rodents, leading to increased glucose disposal. 5-7 Infusion of GLP-1 peptide has also been shown to improve microvascular perfusion in healthy humans, although this was not associated with glucose disposal in one study. 5, [7] [8] [9] Evidence about the effects of GLP-1 receptor agonists or dipeptidyl peptidase-4 inhibitors on the microcirculation, Objective-To assess the effects of glucagon-like peptide (GLP)-1-based therapies (ie, GLP-1 receptor agonists and dipeptidyl peptidase-4 inhibitors) on microvascular function in patients with type 2 diabetes mellitus. Approach and Results-We studied 57 patients with type 2 diabetes mellitus (mean±SD age: 62.8±6.9 years; body mass index: 31.8±4.1 kg/m 2 ; HbA 1c [glycated hemoglobin] 7.3±0.6%) in an acute and 12-week randomized, placebo-controlled, double-blind trial conducted at the Diabetes Center of the VU University Medical Center. In the acute study, the GLP-1 receptor agonist exenatide (therapeutic concentrations) or placebo (saline 0.9%) was administered intravenously. During the 12-week study, patients received the GLP-1 receptor agonist liraglutide (1.8 mg daily), the dipeptidyl peptidase-4 inhibitor sitagliptin (100 mg daily), or matching placebos. Capillary perfusion was assessed by nailfold skin capillary videomicroscopy and vasomotion by laser Doppler fluxmetry, in the fasting state and after a high-fat mixed meal. In neither study, treatment affected fasting or postprandial capillary perfusion compared with placebo (P>0.05). In the fasting state, acute exenatide infusion increased neurogenic vasomotion domain power, while reducing myogenic domain power (both P<0.05). After the meal, exenatide increased endothelial domain power (P<0.05). In the 12-week study, no effects on vasomotion were observed. Conclusions-Despite modest changes in vasomotion, suggestive of sympathetic nervous system activation and improved endothelial function, acute exenatide infusion does not affect skin capillary perfusion in type 2 diabetes mellitus. Twelve-week treatment with liraglutide or sitagliptin has no effect on capillary perfusion or vasomotion in these patients. Our data suggest that the effects of GLP-1-based therapies on glucose are not mediated through microvascular responses.
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however, is scarce. In Wistar rats, 4-week treatment with the GLP-1 receptor agonist liraglutide or the dipeptidyl peptidase-4 inhibitor sitagliptin blunted the inhibiting effects of a high-fat diet on microvascular perfusion. 10 Moreover, we recently demonstrated that acute administration of the GLP-1 receptor agonist exenatide increases microvascular blood flow, independent of NO availability, in healthy overweight men. 11 However, to date, it is unknown whether GLP-1-based therapies affect microvascular perfusion in type 2 diabetes mellitus, a disease that is characterized by reduced microvascular function. 12 Therefore, we assessed the effects of acute exenatide administration and 12-week treatment with liraglutide or sitagliptin on microvascular function in patients with type 2 diabetes mellitus. Given the beneficial effects of GLP-1-based therapies on glucose levels and blood pressure in this population, we hypothesized that these agents increase microvascular perfusion that contributes to these beneficial effects.
Materials and Methods
In the current study, 60 patients with type 2 diabetes mellitus underwent 2 randomized, double-blind, placebo-controlled trials, as described previously 11 : an acute intervention study to assess the effects of intravenous exenatide administration and a 12-week double dummy intervention study to assess the effects of liraglutide 1.8 mg daily or sitagliptin 100 mg daily treatment. In the fasting and postprandial state, microvascular function was assessed using nailfold skin capillary videomicroscopy and laser Doppler fluxmetry. A complete description of Materials and Methods is available in the onlineonly Data Supplement.
Results

Patient Characteristics
Baseline characteristics and study flow diagram are displayed in Figure 1 . Three patients withdrew their consent during the run-in period, and 57 patients were randomized for the acute intervention study (exenatide n=29; placebo n=28). Before randomization for the long-term study, 1 patient was excluded because of incidental findings. Because of adverse effects, 1 patient dropped out in the sitagliptin arm (pollakiuria and dizziness). Thus, analyzes were performed in 55 patients for the long-term study (liraglutide n=19, sitagliptin n=19, and placebo n=17).
Acute Intervention Study: Fasting State
Compared with placebo, acute intervention with exenatide infusion did not affect baseline (+1.0±1.2 capillaries/mm 2 ; P=0.39) or postocclusive capillary density (+1.8±1.3 capillaries/mm 2 ; P=0.18; Table 1 and Figure 2 ).
Exenatide did not affect total vasomotion, nor power in the cardiac, respiratory, and endothelial domains, compared with placebo (P>0.05; Table 1 and Figure 3 ). However, exenatide decreased power in the myogenic domain (log value: 0.05±0.03; P=0.05) and increased power in the neurogenic domain (log value: 0.04±0.01; P=0.004).
Compared with placebo, exenatide increased systolic blood pressure (SBP) by 7.3±3.5 mm Hg (P=0.04), diastolic blood pressure (DBP) by 2.9±1.5 mm Hg (P=0.05), and heart rate (HR) by 4.8±1.6 beats/minute (P<0.01; Table 1 ). Moreover, at the start of the microvascular measurements, exenatide decreased glucose levels by 1.6±0.1 mmol/L (P<0.001) compared with placebo ( Figure 4 ).
Acute Intervention Study: Postprandial State
During placebo infusion, the mixed meal did not affect baseline or postocclusion capillary density compared with fasting measurements (Table 1 ). However, meal ingestion induced an increase in power in the neurogenic vasomotion domain (P=0.018).
Compared with placebo, exenatide did not affect baseline (+0.03±1.5 capillaries/mm 2 ; P=0.99) or postocclusion capillary density (+1.7±2.4 capillaries/mm 2 ; P=0.49) in the postprandial state (Table 1 and Figure 2 ). Moreover, exenatide increased endothelial domain power (log value: 0.05±0.02; P=0.01), without affecting other domains (Table 1 and Figure 3 ).
After the meal, SBP (12.3±3.6 mm Hg; P=0.001) and DBP (+8.1±1.6 mm Hg; P<0.001) increased with exenatide compared with placebo ( Table 1 ). The glucose level at the start of the postprandial microvascular measurements with placebo was 9.9±0.2 mmol/L, whereas this was 4.2±0.3 mmol/L lower with exenatide (P<0.001; Figure 4 ).
12-Week Intervention Study: Fasting State
Compared with placebo, 12-week intervention with neither liraglutide (+1.6±2.5 capillaries/mm 2 ; P=0.506) nor sitagliptin (-0.26±2.5 cap/mm 2 ; P=0.916) affected baseline capillary density ( Figure 2 ). Moreover, we observed no effects on postocclusion capillary density (liraglutide: +2.9±2.9 capillaries/mm 2 ; P=0.330; sitagliptin: +1.8±1.3 capillaries/mm 2 ; P=0.184). Liraglutide and sitagliptin did not alter total vasomotion or specific domains, compared with placebo (Table 2 and Figure 3 ).
After 12-week treatment, liraglutide reduced SBP by 11.5±4.7 mm Hg (P=0.02) and increased HR by 5.8±2.0 beats/minute (P=0.006), compared with placebo ( 
12-Week Intervention Study: Postprandial State
Capillary density was similar between all treatment groups in the postprandial state (Table 2 and Figure 2 ). Moreover, no effect was observed on total vasomotion or specific domains of vasomotion ( Figure 3 ).
After the meal, SBP reduced by 15.6±2.5 mm Hg with liraglutide and by 12.1±5.5 with sitagliptin ( with placebo was 10.3±0.4 mmol/L, whereas this was reduced by 1.3±0.5 mmol/L during both liraglutide and sitagliptin (P<0.01; Figure 4 ).
Correlations
In 
Discussion
This is the first study to assess the effects of GLP-1-based therapies on capillary perfusion in patients with type 2 diabetes mellitus. For a comprehensive assessment, measurements were performed using 2 complementary techniques, capillary videomicroscopy and laser Doppler fluxmetry, after both an acute and 12-week intervention, in both the fasting and postprandial states. In none of the settings, we observed changes in capillary perfusion. However, in the acute setting, exenatide infusion increased fasting neurogenic and reduced myogenic power domains, whereas in the postprandial state, the drug increased endothelial domain power. Nailfold skin capillary videomicroscopy was used to assess microvascular perfusion. 13 Perfusion of capillaries is regulated by alternating the diameter of precapillary arterioles. Many mediators, including insulin and NO, are known to cause vasodilation of precapillary arterioles, leading to an increase in capillary perfusion. 13, 14 In animal studies, GLP-1 peptide infusion increases muscle microvascular perfusion. [5] [6] [7] In healthy volunteers, infusion of GLP-1 improves microvascular perfusion in muscle tissue. 15 We recently demonstrated that exenatide increased skin capillary perfusion in healthy men, using the same techniques and a similar study protocol as used in the current study. 16 It was therefore unexpected to find no effect of exenatide on skin capillary perfusion in patients with type 2 diabetes mellitus in the current study. Such a differential effect in microvascular activity is also known for insulin, which improves microvascular perfusion in healthy volunteers, but has no effect on microvascular function in patients with type 2 diabetes mellitus. 17, 18 This discrepancy is attributed to dysfunction of the endothelium in type 2 diabetes mellitus. Potentially, this mechanism also explains the differential findings with GLP-1 and related therapies. Notably, vascular GLP-1 resistance is present in Ossabaw miniature swine with metabolic syndrome, but not in lean, healthy animals. 19 The microcirculation is present throughout the body, and its physiological role differs depending on the studied organ. For example, muscle microvascular perfusion is involved in muscle glucose uptake. 20 The microcirculation of the skin is largely involved in thermoregulation, by opening and closing of arteriovenous anastomoses. 21 However, because glucose uptake in skin during hyperinsulinemia contributes significantly to whole body glucose uptake, 22 we used capillary videomicroscopy to assess capillary perfusion in a noninvasive way. This allowed us to assess not only capillary perfusion but also functional capillary reserve. 23 By doing so, we and others have repeatedly demonstrated that dorsal nailfold skin microcirculation (capillary density and capillary reserve) is associated with changes in glucose metabolism, 13, 24, 25 in a much similar fashion as muscle microcirculation. However, although insulin-induced changes in skin and muscle microvascular perfusion are correlated, 13 it must be repeated that these vascular beds serve different functions and may therefore respond differently to GLP-1-based therapies. Because glucose levels decreased in both the acute and 12-week studies, without changes in skin microvascular perfusion, future studies should assess whether GLP-1-based therapies affect muscle microcirculation.
Laser Doppler fluxmetry was performed to measure skin microvascular vasomotion, the rhythmic contraction and dilation of arterioles caused by changes in contraction and relaxation of smooth muscle cells in the vessel walls. Vasomotion is considered to be involved in several microvascular aspects, including tissue oxygenation, vascular resistance, maintenance of capillary pressure, and perfusion. 26, 27 Infusion of insulin leads to an increase in both total vasomotion and capillary perfusion, thereby likely allowing for increased glucose and insulin delivery to target cells. 28 Moreover, using component analysis, distinct periodic oscillations in the laser Doppler vasomotion signal have been attributed to cardiac, respiration, and vessel myogenic activity; neurogenic activity; and endothelial activity. As such, the laser Doppler signal can be used for total vasomotion per se, but also to assess aspects of neurogenic and endothelial activity.
Although we did not observe effects on total vasomotion, exenatide acutely increased activity in the neurogenic domain, which reflects an increase in microcirculatory sympathetic nervous system (SNS) activity. 29 This is in line with previous findings, in which GLP-1 receptor agonists were shown to stimulate SNS activity, measured by heart rate variability, 30, 31 or plasma catecholamine levels. 32 Although increased SNS activity is commonly associated with vasoconstriction, several studies have demonstrated that for the microcirculation, SNS activity might be associated with improved perfusion and consequently glucose uptake. 25 For example, in healthy volunteers, clamped hyperinsulinemia increased power in the neurogenic domain, which was associated with increased capillary perfusion and glucose uptake. 25 In line with these findings, here, the exenatide-induced increase in neurogenic power was strongly associated with reduced glucose levels, indicating a SNS-induced increase in glucose uptake. However, this was not accompanied by changes in capillary perfusion. Whether increased neurogenic activity could lower glucose without increasing skin capillary density is unknown, yet differences may exist between healthy volunteers and overweight patients with type 2 diabetes mellitus. Potentially, as discussed above, skin microcirculation does not adequately represent muscle microcirculation, where the largest part of glucose utilization occurs. Interestingly, in a recent study in rats and mice, stimulation of β2-adrenoreceptors in skeletal muscle cells increased glucose uptake independent of the insulin signaling pathway, 33 which could explain the lack of effect on microvascular perfusion. Because we only measured glucose levels, and not muscle glucose uptake, additional studies are needed to assess whether the inverse association between neurogenic activity and glucose levels is mediated by increased glucose uptake.
Interestingly, not all studies are suggestive of increased SNS activity after GLP-1 receptor agonist intervention. For example, we recently demonstrated that exenatide infusion decreased neurogenic activity in healthy overweight men. 16 In that study, the effect on neurogenic activity was negatively correlated with capillary density, leading us to speculate that an exenatide-induced reduction in dermal SNS activity reduces vascular tone and consequently increases capillary density.
Increased neurogenic activity was accompanied by reduced myogenic power, although the latter was statistically rather weak and might be a false-positive finding. Nevertheless, reduced myogenic power is known to occur with vasoconstriction. 34 When combined, 2 distinct mechanisms could be proposed: (1) acute exenatide administration primarily increases SNS activity, leading to vasoconstriction and increased blood pressure; (2) acute exenatide administration increases blood pressure and as a consequence, autoregulatory vasoconstrictive responses maintain stable microvascular perfusion. 3 Exenatide-induced reductions in glucose levels could contribute to both mechanisms, because low glucose levels increase SNS activity and blood pressure; however, none of the subjects experienced symptoms of hypoglycemia. 35 The acute increase in SNS activity with exenatide could have detrimental cardiovascular and metabolic effects when sustained. 36 However, after 12-week intervention with liraglutide or sitagliptin, no SNS increase was observed. This difference could be explained by differences in pharmacodynamics and pharmacokinetics, as is well known with GLP-1-based therapies. For example, although the short-acting GLP-1 receptor agonist exenatide reduces gastric emptying rate, this does not occur with the long-acting GLP-1 receptor agonist liraglutide or sitagliptin. 37 Alternatively, the effects seen with acute intervention wane over time.
Microvascular perfusion and vasomotion are known to increase after meal ingestion, likely to increase the available endothelial surface allowing a more efficient (muscle) glucose disposal. 12, 27, 38 In obesity, this postprandial mechanism is blunted, which is likely caused by insulin resistance and endothelial dysfunction, and associates with impaired postprandial glucose metabolism. 12, 27 In accordance with these previous studies, we observed no effect of the meal on capillary perfusion in the current study. Interestingly, infusion of exenatide increased power in the endothelial domain of vasomotion. This corresponds with the observation that a single subcutaneous dose of exenatide prevents postprandial endothelial dysfunction in subjects with prediabetes or diabetes mellitus, 39, 40 when measured by reactive hyperemia applanation tonometry. However, because we observed no exenatide changes in capillary perfusion or total vasomotion in current trial, it is unclear whether the improvement in endothelial power has physiological relevance.
The current study has some limitations. First, studies were not performed during (pancreas) clamp procedures, and as such, the effects of GLP-1-based therapies on insulin and other hormones could have influenced microvascular measurements. This may also have occurred in the 12-week intervention study, in which glycemic control (HbA 1c and fasting and postprandial glucose) differed between GLP-1-based treatment interventions and placebo. However, although this obscures interpretation of the direct effects of GLP-1 on microvascular function, the results represent real-life effects of these therapeutic agents. Second, we did not perform glucose tracer studies, which would have allowed us to assess the effects of GLP-1-based therapies on muscle glucose uptake. Third, as stated, microvascular assessments were a secondary end point of a larger study, 11 and therefore, the sample size was not based on calculations for this end point. Nevertheless, using data from our previous study in healthy overweight volunteers, a sample size of 15 patients per group was needed, indicating that the a priori sample size was sufficient to detect clinically relevant changes. Finally, including a treatment arm with overweight healthy volunteers would have been interesting, given the recent approval of liraglutide for weight loss treatment. 41 In conclusion, despite acute exenatide-induced increases in fasting skin SNS activity and postprandial endothelial function, no effect on capillary perfusion was observed in patients with type 2 diabetes mellitus. Moreover, 12-week treatment with liraglutide or sitagliptin did not affect capillary perfusion or vasomotion in these patients. Our data suggest that the effects of GLP-1-based therapies on plasma glucose and blood pressure levels are not caused by changes in microvascular function.
